Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
23 November 2023 - 8:01AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
Pascal Touchon, President and Chief Executive Officer, will
participate in a fireside chat at the 6th Annual Evercore ISI
HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m.
EST.
A live webcast of the presentation will be available by visiting
the Investors and Media section of atarabio.com. An archived replay
of the webcast will be available on the Company's website for 30
days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to
develop off-the-shelf cell therapies for difficult-to-treat cancers
and autoimmune conditions, including multiple sclerosis, that can
be rapidly delivered to patients within days. With cutting-edge
science and differentiated approach, Atara is the first company in
the world to receive regulatory approval of an allogeneic T-cell
immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV)
T-cell platform does not require T-cell receptor or HLA gene
editing and forms the basis of a diverse portfolio of
investigational therapies that target EBV, the root cause of
certain diseases, in addition to next-generation AlloCAR-Ts
designed for best-in-class opportunities across a broad range of
non-EBV-associated liquid and solid tumors. Atara is headquartered
in Southern California. For more information, visit atarabio.com
and follow @Atarabio on X (formerly known as Twitter) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231121525276/en/
Investor and Media Relations Alex Chapman Vice President,
Corporate Communications & Investor Relations (805) 456-4772
achapman@atarabio.com Jason Awe, Ph.D. Senior Director, Corporate
Communications & Investor Relations (805) 217-2287
jawe@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jan 2025 to Feb 2025
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Feb 2024 to Feb 2025
